Ledyard National Bank Acquires 335 Shares of Danaher Co. (NYSE:DHR)

Ledyard National Bank lifted its holdings in shares of Danaher Co. (NYSE:DHR) by 5.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,339 shares of the conglomerate’s stock after acquiring an additional 335 shares during the quarter. Ledyard National Bank’s holdings in Danaher were worth $1,762,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in DHR. AdvisorNet Financial Inc boosted its holdings in shares of Danaher by 11.3% during the 1st quarter. AdvisorNet Financial Inc now owns 758 shares of the conglomerate’s stock worth $189,000 after buying an additional 77 shares during the period. CGN Advisors LLC acquired a new position in shares of Danaher in the first quarter valued at approximately $205,000. Austin Private Wealth LLC increased its stake in shares of Danaher by 3.0% during the first quarter. Austin Private Wealth LLC now owns 1,566 shares of the conglomerate’s stock worth $383,000 after purchasing an additional 46 shares during the period. Riverview Trust Co bought a new stake in Danaher in the 1st quarter valued at $119,000. Finally, Dynamic Advisor Solutions LLC grew its holdings in Danaher by 8.3% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 7,744 shares of the conglomerate’s stock valued at $1,934,000 after buying an additional 591 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock valued at $11,042,433 in the last ninety days. 11.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on DHR shares. Wells Fargo & Company assumed coverage on shares of Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 price objective on shares of Danaher in a report on Friday, September 6th. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Barclays increased their price target on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 24th. Finally, Stifel Nicolaus lifted their price objective on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $282.12.

Danaher Stock Performance

NYSE DHR opened at $272.26 on Tuesday. The firm’s fifty day moving average price is $270.82 and its two-hundred day moving average price is $260.34. The stock has a market cap of $201.66 billion, a PE ratio of 46.15, a PEG ratio of 4.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.05 EPS. On average, equities analysts expect that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.